Pfizer and Bioentech have cleared one of the last hurdles in the path to the first Govt-19 vaccine approval. On Tuesday, the FDA released its own assessment of the vaccine and test data of the companies, finding that the vaccine was at least 90% effective and acting similarly in various sub-populations, including the elderly and co-infected. Although they observed mild adverse events that developed in a significant percentage of participants, the company did not see any serious safety concerns. This information is largely consistent with what test participants have previously reported publicly, leading some experts to warn that while the vaccine is safe, public health officials should prepare people for symptoms such as headaches and fatigue. Read the end points with a free subscription and immediately open this story and read the daily end points daily with 94,800+ biopharma advantage – it’s free. record